Evidence map›Paper›PMID 41741628›Full record

ArticleHypertension research : official journal of the Japanese Society of Hypertension2026

Reduction of interstitial fluid retention by combination therapy with dapagliflozin, an SGLT2 inhibitor, and conventional diuretics: comment on a post-hoc analysis of the DAPA-BODY trial.

Takuya Tomaru

Abstract readEditorialComment
PubMed Publisher
In one paragraph

Article in Hypertension research : official journal of the Japanese Society of Hypertension, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Takuya TomaruDepartment of Endocrinology and Metabolism, Dokkyo Medical University, 880 Kita-kobayashi, Mibu, Shimotsuga, Tochigi, Japan. ttomaru@dokkyomed.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Conceptual framework illustrating differential fluid dynamics between SGLT2 inhibitor monotherapy and combination therapy with conventional diuretics in patients with chronic kidney disease. Combination therapy preferentially reduces interstitial fluid while preserving plasma volume, potentially through attenuation of vasopressin activity, natriuresis, and transcapillary fluid shift.

Indexed as

Benzhydryl CompoundsDiureticsExtracellular FluidGlucosidesHypertensionRenal Insufficiency, ChronicSodium-Glucose Transporter 2 InhibitorsDrug Therapy, CombinationHumansBenzhydryl CompoundsdapagliflozinDiureticsGlucosidesSodium-Glucose Transporter 2 InhibitorsBioelectrical impedance analysisInterstitial fluidloop and thiazide diureticsMorning hypertensionSGLT2 inhibitor

Identifiers

PMID41741628

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.